Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

In This Article:

Key Insights

  • The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they collectively have a greater say in management and business strategy

  • The top 25 shareholders own 49% of the company

  • Institutions own 15% of Corvus Pharmaceuticals

Every investor in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 50% to be precise, is individual investors. Put another way, the group faces the maximum upside potential (or downside risk).

Meanwhile, private equity firms make up 16% of the company’s shareholders.

In the chart below, we zoom in on the different ownership groups of Corvus Pharmaceuticals.

View our latest analysis for Corvus Pharmaceuticals

ownership-breakdown
NasdaqGM:CRVS Ownership Breakdown December 11th 2024

What Does The Institutional Ownership Tell Us About Corvus Pharmaceuticals?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Corvus Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corvus Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
NasdaqGM:CRVS Earnings and Revenue Growth December 11th 2024

Our data indicates that hedge funds own 16% of Corvus Pharmaceuticals. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is OrbiMed Advisors LLC with 11% of shares outstanding. With 8.7% and 7.1% of the shares outstanding respectively, Point72 Asset Management, L.P. and Samlyn Capital, LLC are the second and third largest shareholders. Furthermore, CEO Richard Miller is the owner of 2.7% of the company's shares.

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.


Waiting for permission
Allow microphone access to enable voice search

Try again.